Continued ozanimod treatment for the induction of non-responders in the phase 3 True North trial, induced symptomatic clinical response in nearly half of the patients with ulcerative colitis (UC) after 10 weeks in an open-label extension trial (OLE). Furthermore, clinical remission was reached by 19.3% at this timepoint.
“Ozanimod is an oral, sphingosine-1-phosphate (S1P) receptor modulator that selectively targets S1P1 and S1P5 and is approved by the European Union and the USA for the treatment of moderately to severely active UC,” Prof. Remo Panaccione (University of Calgary, Canada) informed . The compound has been evaluated in the randomised, phase 3 True North trial (NCT02435992), which found it to be significantly beneficial over placebo in clinical, endoscopic, and histologic measures. The 150 post-induction non-responders from cohort 1 of the True North trial were enrolled in the OLE. At baseline of True North, the OLE cohort had a mean age of 38.6 years, participants were diagnosed with UC at a mean of 6.6 years ago, and 66% were men. Extensive disease was present in 44%, one-third of the participants used corticosteroids, and 36.7% had been exposed to a TNF inhibitor. The mean total Mayo score was 9.2 at baseline, which was slightly improved to 8.5 at week 10.
At weeks 5 and 10 of the OLE, symptomatic clinical response was attained by 44.0% and 48.7% of the previous non-responders, respectively. Stratifying according to prior biologic exposure resulted in similar proportions achieving symptomatic clinical response: 43.7% for bio-naïve and 45.2% for bio-exposed at week 5, along with 48.3% and 50.0% at week 10, respectively. Due to the relatively small subgroups, further predictive analyses on that effect are scheduled. Prof. Panaccione also remarked that the higher bar of symptomatic clinical remission was achieved by an additional 16.0% at week 5, which increased to 19.3% at week 10.
“In conclusion, patients with moderately to severely active UC, who failed to respond to an initial 10 weeks of ozanimod, may benefit from an additional 5 to 10 weeks of treatment,” Prof. Panaccione stated.
- Panaccione R, et al. Extended therapy with ozanimod for delayed responders to ozanimod in moderately to severely active ulcerative colitis: data from the True North open-label extension study. OP196, UEG Week 2022, 8–11 October, Vienna, Austria.
Copyright ©2022 Medicom Medical Publishers
« Etrasimod shows advantage over placebo in UC Next Article
Fast recapture of response with ozanimod after withdrawal in UC »
Table of Contents: UEGW 2022
Letter from the Editor
UEGW 2022 Highlights Podcast
IBD in 2022
Fast recapture of response with ozanimod after withdrawal in UC
Ozanimod treatment prompted substantial response after failure of response to induction
Etrasimod shows advantage over placebo in UC
Etrasimod reduces adaptive immune cells in the periphery in UC
Favourable maintenance rates for risankizumab also in delayed responders with CD
IL-23 inhibition reduces inflammatory biomarkers in pre-treated UC
Maintained symptom control with mirikizumab in UC
Mirikizumab successfully resolves active histologic inflammation in UC
Upadacitinib for CD: remarkable efficacy in induction therapy
Sustained maintenance results with upadacitinib in UC
Start low with brepocitinib and ritlecitinib in UC
Another chance for TYK2 inhibition in UC
Small molecule obefazimod shows promise in UC
Pivotal results of etrolizumab for CD partly disappointing
Better results for vedolizumab in early CD
Some patients with limited CD may benefit from an early surgical intervention
Dose-interval of adalimumab might be prolonged in CD patients in stable remission
What Is Hot in Upper GI Disorders?
Less ulcer bleeds early after H. pylori eradication in aspirin users
Dupilumab effective in paediatric patients with eosinophilic oesophagitis
Neoplasia in Barrett’s oesophagus: the earlier the intervention, the better the long-term outcome
Hepatology in 2022
Favourable pancreatitis outcomes with procalcitonin-based algorithm to guide antibiotic use
Portal hypertension is associated with poor prognosis in cirrhotic patients
Chances of transplant-free survival in PSC enhanced by colectomy with ileostomy
SARS-CoV-2: Booster doses of key importance for cirrhotic patients
What Is New in Pancreatic Cancer and Pancreatitis?
Fewer long-term interventions after delayed drainage in necrotising pancreatitis
Detection of Europe´s deadliest cancer: much room for improvement
Colorectal Carcinoma: Improving Diagnosis and Therapy
Immunotherapy response may be modulated by microbiome
Computer-aided colonoscopies improved adenoma detection rates
Screening-detected colorectal cancers may have superior surgical outcomes
IMbrave 151 missed primary endpoint in advanced BTC